A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

被引：0
|
作者：
Eng, Cathy
Hart, Lowell L.
Severtsev, Aleksey
Gladkov, Oleg
Mueller, Lothar
Kopp, Mikhail V.
Vladimirov, Vladimir Ivanovich
Langdon, Robert M.
Kotiv, Bogdan
Barni, Sandro
Hsu, Ching
Bolotin, Ellen
Von Roemeling, Reinhard
Schwartz, Brian E.
Bendell, Johanna C.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Florida Canc Specialists SCRI, Ft Myers, FL USA
[3] Cent Clin Hosp 1 OAO, Moscow, Russia
[4] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia
[5] Samara Reg Clin Oncol Dispensary, Samara, Russia
[6] State Med Inst Pyatigorsk, Pyatigorsk, Russia
[7] Nebraska Methodist Hosp, Omaha, NE USA
[8] State Educ Inst, High Profess Educ Mil Med Acad Named SM Kirov, St Petersburg, Russia
[9] Div Oncol, Treviglio, Italy
[10] Daiichi Sankyo Co Ltd, Edison, NJ USA
[11] ArQule Inc, Woburn, MA USA
[12] Sarah Cannon Res Inst, Nashville, TN USA
[13] Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3508
引用
收藏
页数：1
相关论文
共 50 条
  • [21] E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
    Hochster, Howard S.
    Catalano, Paul J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [23] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis
    Eto, T.
    Masuishi, T.
    Matsui, T.
    Anzai, S.
    Suzuki, Y.
    Fukami, Y.
    Suzuki, K.
    Kusano, F.
    Sakai, Y.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [24] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Soda, Hitoshi
    Maeda, Hiromichi
    Hasegawa, Junichi
    Takahashi, Takao
    Hazama, Shoichi
    Fukunaga, Mutsumi
    Kono, Emiko
    Kotaka, Masahito
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    BMC CANCER, 2015, 15
  • [25] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second -line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
    Hecht, J. Randolph
    Cohn, Allen Lee
    Dakhil, Shaker R.
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [26] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Hitoshi Soda
    Hiromichi Maeda
    Junichi Hasegawa
    Takao Takahashi
    Shoichi Hazama
    Mutsumi Fukunaga
    Emiko Kono
    Masahito Kotaka
    Junichi Sakamoto
    Naoki Nagata
    Koji Oba
    Hideyuki Mishima
    BMC Cancer, 15
  • [27] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Naoki Nagata
    Hiromichi Maeda
    Keiichiro Ishibashi
    Keiji Hirata
    Akitaka Makiyama
    Shigeyoshi Iwamoto
    Hiroyoshi Takemoto
    Mitsunobu Imasato
    Yoichiro Yoshida
    Yoshinori Munemoto
    Chihiro Tanaka
    Yoshitaka Morita
    Yoshihiro Hotta
    Atsushi Toyofuku
    Takeshi Nagasaka
    Satoshi Morita
    Junichi Sakamoto
    Hideyuki Mishima
    Medical Oncology, 2019, 36
  • [28] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Nagata, Naoki
    Maeda, Hiromichi
    Ishibashi, Keiichiro
    Hirata, Keiji
    Makiyama, Akitaka
    Iwamoto, Shigeyoshi
    Takemoto, Hiroyoshi
    Imasato, Mitsunobu
    Yoshida, Yoichiro
    Munemoto, Yoshinori
    Tanaka, Chihiro
    Morita, Yoshitaka
    Hotta, Yoshihiro
    Toyofuku, Atsushi
    Nagasaka, Takeshi
    Morita, Satoshi
    Sakamoto, Junichi
    Mishima, Hideyuki
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [29] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Cohn, Allen Lee
    Hecht, J. Randolph
    Dakhil, Shaker
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status
    Watkins, D. J.
    Tabernero, J.
    Schmoll, H.
    Trarbach, T.
    Ramos, F. J.
    Howe, J.
    Brown, H. M.
    Clark, J.
    Hsu, K.
    Lu, B. D.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345